Kyle G Mitchell1, Marcelo V Negrao2, Edwin R Parra3, Jun Li4, Jianhua Zhang4, Hitoshi Dejima3, Ara A Vaporciyan1, Stephen G Swisher1, Annikka Weissferdt5, Mara B Antonoff1, Tina Cascone2, Emily Roarty2, Ignacio I Wistuba3, John V Heymach2, Don L Gibbons6, Jianjun Zhang2, Boris Sepesi7. 1. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: bsepesi@mdanderson.org.
Abstract
BACKGROUND: High tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are leading biomarkers in metastatic non-small cell lung cancer (NSCLC) and predict favorable response to checkpoint inhibitors. We sought to identify clinicopathologic characteristics associated with elevated TMB and PD-L1 expression among patients who underwent resection for NSCLC. METHODS: NSCLC patients undergoing primary resection (2016-2018) were prospectively enrolled in an immunogenomic profiling project. Multiplex immunofluorescence quantified densities (cells/mm2) of CD3+, CD3+CD8+, CD3+CD8+PD-1+, malignant cells (MCs), MCsPD-L1+, CD68+, CD68+PD-L1+, and CD20+ cells. Whole-exome sequencing quantified TMB (mutations/megabase). TMB and MCsPD-L1+ were dichotomized according to the median of each. RESULTS: A total of 55 patients completed multiplex immunofluorescence and whole-exome sequencing profiling. In this sample, 41.8% (23 of 55) had pathologic stage I disease. Median TMB and MCsPD-L1+ were 3.91 and 0.62 cells/mm2, respectively. TMB was higher among smokers (P = .001) and tumors with lymphovascular invasion (LVI) (P = .051). TMB was positively correlated with densities of MCsPD-L1+ (r = 0.293, P = .030), CD68+PD-L1+ (r = 0.289, P = .033), and CD20+ (r = 0.310, P = .043) cells. The density of MCsPD-L1+ was associated with increased CD3+CD8+ (r = 0.319, P = .018) and CD68+PD-L1+ (r = 0.371, P = .005) cells. Patients with PD-L1HighTMBHigh tumors (30.9%, 17 of 55) had higher intratumoral densities of CD3+, CD3+CD8+, CD68+, CD68+PD-L1+, and CD20+ cells. On multivariable analysis LVI was associated with synchronous elevated TMB and PD-L1 expression (odds ratio 3.53, P = .039). CONCLUSIONS: NSCLC tumors with elevated TMB and PD-L1 expression are associated with LVI and increased intratumoral immune cell infiltration. These findings may potentially improve patient selection for checkpoint inhibitor therapy trials in the adjuvant setting.
BACKGROUND:High tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are leading biomarkers in metastatic non-small cell lung cancer (NSCLC) and predict favorable response to checkpoint inhibitors. We sought to identify clinicopathologic characteristics associated with elevated TMB and PD-L1 expression among patients who underwent resection for NSCLC. METHODS:NSCLCpatients undergoing primary resection (2016-2018) were prospectively enrolled in an immunogenomic profiling project. Multiplex immunofluorescence quantified densities (cells/mm2) of CD3+, CD3+CD8+, CD3+CD8+PD-1+, malignant cells (MCs), MCsPD-L1+, CD68+, CD68+PD-L1+, and CD20+ cells. Whole-exome sequencing quantified TMB (mutations/megabase). TMB and MCsPD-L1+ were dichotomized according to the median of each. RESULTS: A total of 55 patients completed multiplex immunofluorescence and whole-exome sequencing profiling. In this sample, 41.8% (23 of 55) had pathologic stage I disease. Median TMB and MCsPD-L1+ were 3.91 and 0.62 cells/mm2, respectively. TMB was higher among smokers (P = .001) and tumors with lymphovascular invasion (LVI) (P = .051). TMB was positively correlated with densities of MCsPD-L1+ (r = 0.293, P = .030), CD68+PD-L1+ (r = 0.289, P = .033), and CD20+ (r = 0.310, P = .043) cells. The density of MCsPD-L1+ was associated with increased CD3+CD8+ (r = 0.319, P = .018) and CD68+PD-L1+ (r = 0.371, P = .005) cells. Patients with PD-L1HighTMBHigh tumors (30.9%, 17 of 55) had higher intratumoral densities of CD3+, CD3+CD8+, CD68+, CD68+PD-L1+, and CD20+ cells. On multivariable analysis LVI was associated with synchronous elevated TMB and PD-L1 expression (odds ratio 3.53, P = .039). CONCLUSIONS:NSCLC tumors with elevated TMB and PD-L1 expression are associated with LVI and increased intratumoral immune cell infiltration. These findings may potentially improve patient selection for checkpoint inhibitor therapy trials in the adjuvant setting.
Authors: Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245
Authors: Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245
Authors: Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders Journal: Clin Cancer Res Date: 2014-04-08 Impact factor: 12.531
Authors: Ricardo E Vilain; Alexander M Menzies; James S Wilmott; Hojabr Kakavand; Jason Madore; Alexander Guminski; Elizabeth Liniker; Benjamin Y Kong; Adam J Cooper; Julie R Howle; Robyn P M Saw; Valerie Jakrot; Serigne Lo; John F Thompson; Matteo S Carlino; Richard F Kefford; Georgina V Long; Richard A Scolyer Journal: Clin Cancer Res Date: 2017-05-16 Impact factor: 12.531
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Hui Yu; Zhengming Chen; Karla V Ballman; Mark A Watson; Ramaswamy Govindan; Irena Lanc; David G Beer; Raphael Bueno; Lucian R Chirieac; Michael Herman Chui; Guoan Chen; Wilbur A Franklin; David R Gandara; Carlo Genova; Kristine A Brovsky; Mary-Beth M Joshi; Daniel T Merrick; William G Richards; Christopher J Rivard; David H Harpole; Ming-Sound Tsao; Adrie van Bokhoven; Frances A Shepherd; Fred R Hirsch Journal: J Thorac Oncol Date: 2018-09-22 Impact factor: 15.609
Authors: Matthew D Hellmann; Tavi Nathanson; Hira Rizvi; Benjamin C Creelan; Francisco Sanchez-Vega; Arun Ahuja; Ai Ni; Jacki B Novik; Levi M B Mangarin; Mohsen Abu-Akeel; Cailian Liu; Jennifer L Sauter; Natasha Rekhtman; Eliza Chang; Margaret K Callahan; Jamie E Chaft; Martin H Voss; Megan Tenet; Xue-Mei Li; Kelly Covello; Andrea Renninger; Patrik Vitazka; William J Geese; Hossein Borghaei; Charles M Rudin; Scott J Antonia; Charles Swanton; Jeff Hammerbacher; Taha Merghoub; Nicholas McGranahan; Alexandra Snyder; Jedd D Wolchok Journal: Cancer Cell Date: 2018-04-12 Impact factor: 31.743
Authors: Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz Journal: Nat Biotechnol Date: 2013-02-10 Impact factor: 54.908
Authors: Melanie Biesinger; Nele Eicken; Alexander Varga; Michael Weber; Milos Brndiar; Georg Erd; Peter Errhalt; Klaus Hackner; Sarah Hintermair; Alexander Petter-Puchner; Axel Scheed; Elisabeth Stubenberger; Bahil Ghanim Journal: Cancers (Basel) Date: 2022-04-08 Impact factor: 6.575